infect
human
mous
macaqu
model
respect
includ
vivo
neutral
strain
resist
broadli
neutral
antibodi
use
novel
human
mous
model
demonstr
lsevhlsf
rapidli
mobil
nk
cell
elimin
cell
vivo
day
administr
capac
lsevhlsf
elimin
cell
via
adcc
combin
broad
neutral
activ
support
potenti
use
immunotherapeut
agent
elimin
reactiv
latent
cell
deplet
reservoir
keyword
nk
cell
human
immunodefici
viru
b
ind
human
immunodefici
viru
type
envelop
neutral
viral
infect
prevent
viral
entri
subsequ
infect
cell
constitut
major
mechan
util
broadli
neutral
antibodi
bnab
control
infect
antibodi
also
util
anoth
mechan
inhibit
infect
antibodydepend
cellular
cytotox
adcc
mediat
bind
envelop
molecul
express
surfac
infect
cell
util
constant
fc
domain
recruit
effector
cell
nk
cell
kill
infect
cell
adccmedi
elimin
reactiv
latent
cell
potenti
mechan
antibodi
markedli
reduc
reservoir
contribut
function
cure
like
effect
therapeut
antibodi
treat
individu
bnab
dual
capac
potent
neutral
broad
rang
isol
effect
mobil
adcc
elimin
cell
includ
reactiv
latent
infect
cell
howev
despit
capac
potent
bnab
neutral
isol
test
markedli
suppress
viremia
infus
patient
elimin
cell
adcc
rapid
emerg
expans
bnabresist
bnab
monotherapi
limit
efficaci
bnab
monotherapi
would
like
also
limit
capac
mobil
adcc
overcom
limit
prevent
delay
vivo
emerg
bnabresist
develop
bispecif
hexaval
fusion
protein
compos
two
engin
domain
specif
differ
neutral
epitop
engin
mutant
extracellular
domain
select
bind
site
antibodi
domain
target
highli
conserv
coreceptorbind
site
bind
induc
full
exposur
epitop
linkag
solubl
onedomain
domain
greatli
augment
bind
neutral
activ
bispecif
hexaval
fusion
protein
consist
four
molecul
two
molecul
link
heavychain
constant
domain
kappa
lightchain
constant
domain
ck
fc
domain
potenti
hexaval
bind
increas
avid
enabl
neutral
potent
nativ
bnab
furthermor
bispecif
bind
two
independ
epitop
constrain
vivo
emerg
requir
independ
mutat
target
site
report
combin
bnab
treatment
final
design
mirror
structur
mutat
reduc
bind
parallel
decreas
bind
would
diminish
replic
capac
therebi
inhibit
emerg
escap
mutat
gener
structur
variant
lsevhl
significantli
increas
vivo
halflif
due
improv
structur
stabil
increas
bind
fcrn
augment
capac
lsevhl
mobil
adcc
activ
defucosyl
fc
domain
increas
affin
therebi
amplifi
abil
recruit
effector
cell
current
studi
examin
vitro
vivo
activ
defucosyl
lsevhl
name
lsevhlsf
luciferas
report
gene
incub
cell
cho
cell
fig
previous
develop
human
mous
model
evalu
vivo
capac
human
nk
cell
activ
superagonist
complex
inhibit
infect
construct
intrasplen
inject
immunodefici
nsg
mice
activ
human
pbmc
husplpbmcnsg
mice
activ
human
pbmc
includ
cell
nk
cell
persist
mous
spleen
least
month
intrasplen
inject
becom
infect
intrasplen
inocul
support
adcc
activ
week
intrasplen
inject
husplpbmcnsg
mice
env
lucr
rapid
expans
number
cell
mous
spleen
visual
sequenti
ivi
imag
untreat
husplpbmcnsg
mice
fig
first
step
use
mice
evalu
vivo
activ
lsevhlsf
compar
vivo
pharmacokinet
lsevhlsf
nsg
mice
day
intraven
inject
lsevhlsf
serum
level
less
serum
level
still
inhibitori
concentr
ic
strain
jrcsf
fig
investig
capac
lsevhlsf
inhibit
vivo
infect
challeng
husplpbmcnsg
mice
either
jrcsf
lucr
lucr
virus
one
day
later
group
mice
either
left
untreat
intraven
inject
lsevhlsf
isotyp
control
monoclon
antibodi
mab
five
day
later
infect
evalu
measur
lucr
activ
splenic
lysat
lsevhlsf
potent
suppress
infect
jrcsf
lucr
viru
fig
contrast
despit
serum
level
lsevhlsf
fig
lsevhlsf
significantli
p
inhibit
infect
strain
lucr
fig
adapt
husplpbmcnsg
mice
use
novel
vivo
model
evalu
adcc
activ
investig
vivo
capac
defucosyl
lsevhlsf
elimin
cell
husplpbmcnsg
mice
infect
intrasplen
inject
jrcsf
lucr
five
day
later
vivo
infect
establish
mice
either
left
untreat
treat
lsevhlsf
isotyp
control
mab
full
replic
primari
cell
take
least
h
posit
reduct
lucr
activ
measur
day
treatment
indic
elimin
cell
adcc
one
day
jrcsf
lucrinfect
husplpbmcnsg
mice
treat
lsevhlsf
number
cell
mous
spleen
indic
lucr
activ
reduc
almost
compar
treatment
control
mab
greater
p
reduct
mediat
treatment
fig
vivo
visual
product
infect
cell
ivi
imag
demonstr
mark
reduct
lucr
activ
spleen
husplpbmcnsg
mice
treat
lsevhlsf
compar
spleen
untreat
husplpbmcnsg
mice
fig
human
hing
calcul
molecular
mass
shown
parenthes
b
highresolut
mass
spectrometri
analysi
lsevhl
produc
cell
design
lsevhl
lsevhl
produc
gft
gene
knockout
cell
design
lsevhlsf
mass
spectra
shown
deconvolut
mass
major
peak
indic
top
fc
oligosaccharid
without
galactos
fucos
fc
oligosaccharid
without
galactos
fucos
c
bind
kinet
lsevhl
lsevhlsf
recombin
human
measur
spr
spr
analysi
perform
biacor
use
singlecycl
approach
accord
manufactur
instruct
analyt
test
nm
concentr
kinet
constant
shown
right
calcul
sensogram
fit
monoval
bind
model
evalu
softwar
k
associ
rate
constant
k
dissoci
rate
constant
k
equilibrium
dissoci
constant
confirm
lsevhlsfmedi
reduct
infect
consequ
nk
cellmedi
adcc
deplet
nk
cell
popul
pbmc
prior
inject
husplpbmcnsg
mice
examin
whether
would
abrog
lsevhlsf
activ
nsg
mice
intrasplen
inject
either
unfraction
pbmc
nk
celldeplet
pbmc
intrasplen
infect
jrcsf
lucr
five
day
later
human
mice
either
left
untreat
treat
lsevhlsf
day
later
infect
spleen
quantifi
measur
lucr
activ
describ
lsevhlsf
treatment
markedli
reduc
infect
spleen
nsg
mice
construct
intrasplen
inject
unfraction
pbmc
contrast
lsevhlsf
treatment
decreas
infect
spleen
nsg
mice
intrasplen
inject
nk
celldeplet
pbmc
fig
activ
nk
cell
increas
capac
mediat
adcc
exampl
adccmedi
vivo
elimin
human
b
cell
lymphoma
cell
via
nk
cell
recruit
mab
significantli
increas
nk
cell
activ
bival
fusion
protein
bind
two
mutant
molecul
previous
demonstr
vivo
treatment
husplpbmcnsg
mice
activ
human
nk
cell
popul
mous
spleen
enabl
potent
reduc
intrasplen
infect
determin
whether
activ
nk
cell
increas
lsevhlsfmedi
deplet
cell
infect
husplpbmcnsg
mice
jrcsf
lucr
day
later
either
treat
mice
treat
mice
lsevhlsf
combin
experi
reduc
treatment
dose
lsevhlsf
half
enabl
us
identifi
addit
effect
treatment
lsevhlsfmedi
deplet
cell
combin
lsevhlsf
reduc
jrcsf
lucr
infect
treatment
either
lsevhlsf
alon
fig
taken
togeth
result
demonstr
bispecif
hexaval
antibodi
lsevhlsf
potent
inhibit
infect
well
markedli
reduc
establish
infect
via
nk
celldepend
adcc
could
enhanc
activ
nk
cell
examin
capac
lsevhlsf
inhibit
acut
shiv
infect
rhesu
macaqu
day
infect
shiv
prior
onset
peak
viremia
inject
either
lsevhlsf
mgkg
phosphatebuff
salin
pb
shiv
rna
plasma
measur
indic
time
fig
pbstreat
anim
reach
peak
infect
averag
day
infect
suppress
lsevhlsf
treatment
day
fig
wellrecogn
limit
macaqu
studi
involv
cost
logist
factor
limit
number
anim
avail
inclus
experiment
group
number
anim
group
rel
small
case
present
studi
variat
larg
typic
macaqu
signific
quantit
effect
may
identifi
direct
statist
comparison
control
group
individu
variat
viremia
seen
macaqu
therefor
evalu
statist
signific
differ
treat
untreat
macaqu
normal
viru
rna
divid
valu
viru
rna
day
subtract
administr
lsevhlsf
day
vivo
jrcsf
lucr
infect
visual
use
ivi
imag
day
viral
inocul
imag
acquir
min
substrat
inject
correct
background
bioluminesc
scan
two
repres
mice
shown
b
pharmacokinet
lsevhlsf
vivo
nsg
mice
nsg
mice
n
inject
either
lsevhlsf
serum
collect
h
day
day
day
day
later
level
antibodi
serum
sampl
determin
use
elisa
result
present
log
scale
dot
line
graph
indic
lsevhlsf
level
neutral
ic
g
least
ic
g
vitro
c
husplpbmcnsg
mice
inocul
env
lucr
express
env
strain
jrcsf
c
env
strain
next
day
group
mice
either
left
untreat
treat
mg
either
lsevhlsf
control
antibodi
five
day
later
infect
mice
measur
quantifi
lucr
activ
splenic
lysat
dot
plot
graph
display
percent
neutral
mous
treat
indic
treatment
compar
untreat
group
group
mean
sd
repres
pool
data
independ
experi
use
differ
donor
c
independ
experi
use
differ
donor
result
highli
statist
signific
p
reduct
peak
viremia
day
compar
peak
viremia
untreat
macaqu
fig
subsequ
time
point
trend
lower
viru
rna
concentr
treat
untreat
macaqu
day
p
statist
signific
decreas
viru
rna
fig
vivo
result
correspond
potent
capac
lsevhlsf
neutral
vitro
shiv
infect
ic
gml
ic
gml
fig
determin
whether
transitori
inhibitori
effect
lsevhlsf
shiv
viremia
due
short
serum
halflif
measur
lsevhlsf
pharmacokinet
infect
macaqu
lsevhlsf
serum
concentr
high
gml
day
infus
rapidli
decreas
gml
day
infus
concentr
unlik
effect
suppress
vivo
shiv
replic
fig
one
month
infect
macaqu
sacrif
shiv
infect
macaqu
tissu
evalu
level
shiv
rna
ileum
rectum
duodenum
colon
lsevhlsftreat
macaqu
shiv
rna
level
significantli
lower
untreat
group
fig
level
shiv
rna
lymph
node
inguin
mesenter
axillari
brain
testisovari
compar
fig
thu
lsevhlsf
highli
effect
suppress
vivo
shiv
replic
durabl
vivo
inhibitori
effect
singl
dose
shiv
replic
limit
rel
short
serum
halflif
lsevhlsf
antibodi
elimin
cell
adcc
recruit
innat
immun
effector
cell
particularli
nk
cell
lyse
infect
cell
exocytosi
granzym
perforin
may
contribut
prevent
control
infect
support
studi
correl
magnitud
adcc
activ
protect
vaccin
trial
subject
slower
progress
infect
control
infect
elit
control
vivo
efficaci
bnab
therapi
emerg
immun
escap
variant
acceler
elimin
cell
human
mice
adcc
activ
correl
total
igg
bound
cell
bispecif
hexaval
bind
lsevhlsf
spatial
adjac
coreceptorbind
site
favor
multival
target
individu
trimer
molecul
membran
whose
wide
separ
may
otherwis
prevent
effici
bival
bind
monospecif
natur
bnab
therebi
increas
capac
mobil
adccmedi
elimin
cell
use
strategi
report
enhanc
vivo
adcc
activ
antibodi
use
cancer
therapi
defucosyl
lsevhlsf
increas
affin
fc
domain
innat
effector
cell
therebi
increas
capac
mediat
hivspecif
adcc
activ
develop
husplpbmcnsg
human
mous
model
contain
human
nk
cell
high
cytotox
function
vivo
system
evalu
adcc
activ
mediat
lsevhlsf
full
replic
primari
cell
take
least
h
postul
reduct
level
infect
day
treatment
lsevhlsf
bnab
indic
adccmedi
vivo
elimin
cell
rather
suppress
new
infect
antibodi
neutral
activ
level
infect
husplpbmcnsg
mice
reduc
day
lsevhlsf
treatment
greater
reduct
mediat
treatment
fig
result
confirm
direct
vivo
imag
lsevhlsftreat
mice
ivi
scan
fig
nk
cell
deplet
abrog
lsevhlsfmedi
reduct
infect
indic
elimin
cell
lsevhlsf
mediat
adcc
fig
support
find
activ
nk
cell
cytotox
activ
treatment
increas
lsevhlsfmedi
vivo
reduct
infect
fig
addit
permit
us
determin
vivo
adcc
activ
lsevhlsf
husplpbmcnsg
human
mous
model
develop
vivo
adcc
evalu
provid
investig
crucial
highthroughput
model
identifi
antibodi
includ
mutat
fc
domain
immunomodul
potent
vivo
capac
mobil
adcc
activ
elimin
cell
vivo
studi
human
mice
macaqu
human
demonstr
treatment
singl
bnab
potent
prevent
suppress
infect
possibl
reduc
latent
reservoir
fc
domainmedi
recruit
effector
cell
adcc
howev
limit
current
bnab
singl
bnab
neutral
strain
enabl
emerg
immun
escap
variant
mutat
bnabspecif
epitop
like
preexist
mutant
viru
mediat
recurr
viremia
singl
amino
acid
mutat
enabl
escap
natur
bnab
major
impedi
current
limit
efficaci
bnab
monotherapi
substanti
number
individu
popul
preexist
viru
consequ
treatment
individu
minim
suppress
viremia
also
rapidli
emerg
analyt
antiretrovir
therapi
art
treatment
interrupt
studi
patient
administr
respect
consequ
treatment
combin
bnab
specif
nonoverlap
epitop
requir
adccmedi
elimin
cell
infect
immun
escap
variant
prevent
recurr
viremia
effectu
resist
viru
emul
success
strategi
combin
differ
antiretrovir
drug
previous
demonstr
bispecif
fc
domain
fusion
protein
express
epitopespecif
human
antibodi
domain
display
potent
vitro
neutral
activ
fc
domain
fusion
protein
express
either
alon
target
two
independ
epitop
lsevhlsf
contribut
potent
broad
neutral
activ
enabl
mediat
adcc
elimin
also
constrain
vivo
emerg
lsevhlsfresist
escap
mutant
requir
mutat
two
nonoverlap
epitop
immun
escap
demonstr
vivo
inhibitori
activ
lsevhlsf
shiv
use
human
mous
model
nonhuman
primat
model
respect
breadth
lsevhlsf
activ
demonstr
vitro
neutral
env
strain
lsevhlsf
fig
vivo
inhibit
infect
strain
also
shown
resist
fig
altern
approach
combin
therapi
two
differ
bnab
target
nonoverlap
epitop
gener
bispecif
igg
molecul
consist
antigenbind
fragment
two
differ
bnab
link
fc
domain
lsevhlsf
combin
subunit
coreceptorbind
sitespecif
antibodi
fragment
differ
bispecif
antibodi
three
crucial
way
first
instead
use
bnab
domain
recogn
bind
site
util
onedomain
mutat
exhibit
high
solubl
stabil
retain
bind
env
mimick
bind
escap
mutant
display
compromis
viral
replic
due
reduc
capac
mutat
bind
initi
cellular
entri
subsequ
infect
second
engag
bind
site
induc
exposur
antibodi
epitop
major
target
antibodi
circul
infect
patient
mediat
adcc
boost
capac
elimin
cell
via
adcc
third
bispecif
hexaval
bind
lsevhlsf
may
increas
avid
beyond
natur
monospecif
bival
antibodi
capabl
mediat
adcc
facilit
bind
limit
number
molecul
express
surfac
cell
enhanc
avid
lsevhlsf
express
infect
cell
indic
increas
bind
cell
compar
fig
two
day
treatment
macaqu
acut
shiv
infect
lsevhlsf
peak
viremia
suppress
log
compar
untreat
macaqu
fig
similar
approach
use
demonstr
alon
combin
suppress
acut
shiv
infect
reduc
seed
cellassoci
viral
reservoir
experiment
protocol
studi
differ
sustain
bnabmedi
viral
suppress
initi
art
day
bnab
treatment
reduct
plasma
viru
rna
induc
day
lsevhlsf
treatment
correspond
k
day
higher
k
day
calcul
macaqu
chronic
infect
shiv
treat
bnab
indic
lsevhlsf
display
potent
antiretrovir
activ
mark
reduct
shiv
infect
lsevhlsftreat
macaqu
mucos
tissu
may
consequ
signific
reduct
peak
viremia
mediat
lsevhlsf
reduct
shivinfect
mucos
tissu
unlik
due
elimin
shivinfect
cell
lsevhlsfmedi
adcc
speci
differ
specif
affin
human
fc
domain
macaqu
fc
receptor
may
limit
capac
mobil
adcc
macaqu
lsevhlsf
plasma
level
averag
gml
first
day
administr
level
subsequ
declin
rapidli
bnab
previous
describ
sever
factor
may
contribut
shorter
halflif
lsevhlsf
nativ
bnab
includ
reduc
abil
interact
gener
extrem
stabl
heterodim
increas
suscept
proteolyt
degrad
associ
use
polypeptid
linker
link
fc
scaffold
investig
new
approach
enhanc
halflif
lsevhlsf
nevertheless
potent
capac
neutral
strain
resist
bnab
elimin
cell
counterbal
shorter
halflif
support
potenti
inclus
short
intens
cours
lsevhlsf
compon
therapeut
regimen
combin
immunostimul
latencyreactiv
agent
reduc
reservoir
contribut
final
goal
erad
nih
bethesda
md
process
cell
cultur
supernat
describ
previous
defucosyl
lsevhl
lsevhlsf
produc
use
cho
cell
gdpfucos
transport
gft
gene
inactiv
use
cluster
regularli
interspac
short
palindrom
repeat
crispr
system
describ
previous
briefli
three
gdpfucos
transport
gene
dna
fragment
target
cgctggtcgtctctctctac
target
agataggggtatccagctgc
target
gtacttg
ttgaggaatacca
clone
pcasguidegfp
vector
origen
technolog
rockvil
md
transfect
cho
cell
use
polyfect
qiagen
frederick
md
accord
manufactur
protocol
three
day
transfect
green
fluoresc
protein
gfp
posit
singl
cell
sort
plate
expand
success
gdpfucos
transport
gene
delet
one
cho
cell
knockout
mutant
clone
demonstr
mass
spectral
analysi
purifi
antibodi
obtain
transient
antibodi
express
adapt
growth
serumfre
medium
transfect
lsevhl
vector
establish
stabl
cell
line
produc
lsevhlsf
use
standard
glutamin
synthetasebas
select
system
lsevhl
lsevhlsf
purifi
cell
cultur
supernat
protein
asepharos
fast
flow
column
chromatographi
ge
healthcar
piscataway
township
nj
describ
previous
highresolut
ms
protein
mix
buffer
guanidinehcl
trishcl
mm
edta
presenc
mm
dithiothreitol
dtt
incub
min
mass
spectrometri
ms
data
acquir
agil
accuratemass
qtof
lcm
system
agil
technolog
danburi
ct
equip
dual
electrospray
sourc
oper
positiveion
mode
separ
perform
zorbax
poroshel
column
mm
mm
particl
size
analyt
elut
flow
rate
mlmin
organ
gradient
min
hold
organ
min
mobil
phase
water
acetonitril
contain
formic
acid
instrument
use
fullscan
timeofflight
tof
mode
ms
sourc
paramet
set
capillari
voltag
kv
fragmentor
voltag
v
skimmer
voltag
v
ga
temperatur
dri
ga
flow
litersmin
nebul
pressur
lbin
gaug
data
acquir
high
resolut
mz
ghz
tofmass
spectra
record
across
rang
mz
mass
accuraci
maintain
run
time
infus
intern
mass
calibr
sampl
continu
liquid
chromatographi
lc
ms
run
data
acquisit
perform
use
mass
hunter
work
station
agil
version
data
analysi
deconvolut
mass
spectra
perform
use
mass
hunter
qualit
analysi
softwar
agil
version
bioconfirm
workflow
spr
kinet
affin
lsevhl
lsevhlsf
bind
quantifi
surfac
plasmon
reson
spr
analysi
biacor
instrument
ge
healthcar
port
washington
ny
use
singlecycl
approach
accord
manufactur
instruct
briefli
purifi
protein
dilut
sodium
acet
ph
immobil
directli
onto
sensor
chip
standard
amin
coupl
method
refer
cell
inject
carbodiimid
ethanolamin
without
inject
analyt
test
nm
concentr
kinet
constant
calcul
sensogram
fit
monoval
bind
model
evalu
softwar
gener
infecti
molecular
clone
inhibit
vitro
vivo
infect
determin
util
lucr
reporterexpress
infecti
molecular
clone
imc
system
provir
genom
engin
express
ci
lucr
report
gene
heterolog
env
gene
sequenc
choic
approach
well
establish
multipl
context
includ
evalu
vitro
vivo
inhibitori
capac
antibodi
nk
cell
cell
dualaffin
retarget
protein
dart
microbicid
provir
plasmid
collect
refer
carri
env
gene
indic
transient
transfect
cell
produc
viru
stock
imc
express
lucr
env
lucr
env
lucr
report
virus
replic
compet
continu
express
lucr
multipl
cycl
replic
permit
highli
sensit
specif
detect
activ
replic
sever
week
inocul
lucr
short
cellular
halflif
approxim
h
measur
lucr
level
correl
activ
replic
experi
use
env
lucr
virus
env
strain
jrcsf
bal
clade
b
clade
c
resist
env
strain
clade
b
clade
c
env
also
resist
neutral
bnab
infecti
titer
env
lucr
virus
averag
infecti
unit
iu
ml
determin
limitingdilut
infect
assay
use
tzmbl
cell
describ
previous
assay
antibodi
bind
cell
surfac
env
bind
lsevhlsf
env
trimer
express
surfac
infect
cell
comparison
bind
perform
flow
cytometr
analysi
lsevhlsf
control
mab
recogn
ebola
viru
biotinyl
use
ezlink
sulfonhslcbiotin
life
technolog
follow
desalt
step
use
zeba
spin
desalt
column
life
technolog
cell
latent
infect
cell
line
use
model
latenc
activ
phorbol
myrist
acet
pma
ngml
h
stain
biotinyl
antibodi
indic
concentr
determin
biotinyl
min
follow
wash
incub
streptavidinphycoerythrin
pe
life
technolog
dilut
min
data
acquir
use
lsr
ii
flow
cytomet
bd
bioscienc
analyz
flowjo
softwar
flowjo
ashland
vitro
neutral
assay
human
pbmc
capac
lsevhlsf
neutral
env
lucr
express
envelop
bal
lucr
jrcsf
lucr
lucr
lucr
lucr
lucr
lucr
lucr
virus
determin
use
modifi
vitro
human
pbmcbase
assay
describ
previous
human
pbmc
isol
naiv
donor
activ
phytohemagglutinin
pha
gml
uml
cultur
rpmi
ad
heatinactiv
fetal
bovin
serum
fb
volvol
penicillin
uml
streptomycin
gml
glutamin
mm
hepe
mm
one
day
later
env
lucr
virus
iu
coincub
h
roundbottom
plate
dilut
nm
nm
either
lsevhlsf
activ
pbmc
harvest
wash
resuspend
medium
ad
well
cellswel
antibodyviru
mixtur
place
cultur
h
supernat
aspir
cell
lyse
lucr
assay
lysi
buffer
lwell
lucr
activ
aliquot
l
lysat
measur
use
renilla
luciferas
assay
system
promega
madison
wi
describ
previous
vitro
adcc
assay
target
cell
cho
cell
cho
cell
stabli
express
cladeb
env
cell
suspend
plate
cellswel
plate
lwell
indic
concentr
lsevhlsf
dilut
ad
well
lwell
effector
cell
genet
modifi
jurkat
cell
express
human
luciferas
report
gene
transcript
control
nfatr
promega
ad
cellswel
l
targeteffector
cell
ratio
overnight
incub
bioglo
luciferas
assay
reagent
promega
ad
luminesc
quantifi
rel
luminesc
unit
rlu
measur
use
luminesc
plate
reader
pharmacokinet
measur
serum
level
lsevhlsf
mice
rhesu
macaqu
nsg
mice
intraven
inject
mg
either
lsevhlsf
day
plasma
sampl
collect
submandibular
bleed
indic
time
inject
chineseorigin
rhesu
macaqu
intraven
inject
lsevhlsf
mgkg
day
shiv
infect
plasma
sampl
collect
day
plasma
concentr
lsevhlsf
determin
enzymelink
immunosorb
assay
elisa
plate
coat
env
standard
curv
gener
use
lsevhlsf
standard
describ
previous
vivo
capac
lsevhlsf
inhibit
infect
determin
use
previous
describ
human
mous
model
nsg
mice
intrasplen
inject
activ
human
pbmc
husplpbmcnsg
mice
briefli
human
pbmc
isol
donor
cultur
activ
pha
gml
uml
h
experi
nk
cell
remov
pbmc
activ
immunomagnet
sort
use
antihuman
microbead
miltenyi
biotec
cambridg
deplet
confirm
flow
cytometr
analysi
stain
antihuman
antihuman
biolegend
antibodi
describ
previous
next
day
activ
pbmc
nk
celldeplet
pbmc
wash
twice
steril
pb
ad
pbmc
activ
pbmc
cell
centrifug
h
rpm
resuspend
inject
intrasplen
cellsmous
nsg
mice
jackson
laboratori
bar
harbor
mice
bred
maintain
biosafeti
level
enhanc
anim
facil
albert
einstein
colleg
medicin
describ
previous
capac
lsevhlsf
inhibit
infect
evalu
intraven
inject
husplpbmcnsg
mice
mg
lsevhlsf
mg
day
intrasplen
inocul
indic
env
lucr
neg
control
use
monoclon
antibodi
middl
east
respiratori
syndrom
coronaviru
level
infect
engraft
human
pbmc
husplpbmcnsg
mous
spleen
quantifi
measur
lucr
activ
mous
splenic
lysat
use
renilla
luciferas
assay
system
promega
previous
describ
enabl
us
combin
result
multipl
experi
statist
analysi
result
report
percent
neutral
infect
treatment
group
refer
untreat
group
use
formula
treat
group
rlu
untreat
group
rlu
determin
vivo
capac
lsevhlsf
elimin
cell
husplpbmcnsg
mice
nsg
mice
intrasplen
inject
nk
celldeplet
pbmc
cellsmous
intraven
inject
either
lsevhlsf
mg
mg
day
infect
indic
env
lucr
provid
time
establish
vivo
infect
suffici
target
evalu
effect
adccmedi
elimin
cell
experi
mice
intraven
inject
lsevhlsf
mg
andor
subcutan
inject
dose
mgkg
provid
mice
maximum
concentr
serum
c
max
nm
day
treatment
reduct
number
cell
mous
spleen
determin
quantifi
decreas
lucr
activ
compar
lucr
level
untreat
group
use
formula
treat
group
rlu
untreat
group
rlu
ivi
imag
vivo
infect
husplpbmc
mice
visual
quantifi
bioluminesc
imag
use
ivi
spectrum
imag
calip
lifesci
hopkinton
mice
intraven
inject
gmous
bioluminesc
substrat
rediject
coelenterazin
h
calip
life
scienc
imag
analyz
use
wizard
bioluminesc
select
tool
automat
wavelength
exposur
detect
bioluminesc
grayscal
imag
overlaid
use
livingimag
softwar
packag
creat
pseudocolor
imag
repres
bioluminesc
intens
bioluminesc
intens
luciferas
activ
mous
spleen
quantifi
use
livingimag
softwar
packag
report
photon
countssecond
eight
healthi
male
femal
chineseorigin
rhesu
macaqu
randomli
assign
two
group
four
inject
intraven
shiv
tissu
cultur
infect
dose
tcid
day
later
intraven
inject
lsevhl
pb
whole
blood
collect
day
anim
sacrif
day
tissu
sampl
collect
store
vitro
neutral
shiv
lsevhlsf
evalu
use
tzmbl
assay
briefli
serial
dilut
lsevhlsf
irrelev
control
antibodi
preincub
shiv
h
ad
tzmbl
cell
plate
luciferas
express
quantifi
h
infect
upon
cell
lysi
addit
luciferas
substrat
invitrogen
precis
measur
viral
rna
plasma
necropsi
tissu
util
new
ultrasensit
nest
quantit
realtim
pcr
rtqpcr
method
target
highli
conserv
region
simian
immunodefici
viru
siv
gag
sivshiv
rna
load
plasma
tissu
quantifi
extract
rna
either
plasma
l
use
qiaamp
viral
rna
minikit
qiagen
tissu
mg
pulver
stainless
steel
grind
ball
homogen
trizol
reagent
follow
manufactur
recommend
use
nest
primer
gatttggattagcagaaa
gcctgttg
gttggtctacttgtttttggcatagtttc
flank
siv
gag
target
region
revers
transcript
preamplif
rna
revers
transcrib
cdna
use
nest
primer
facilit
prime
specif
target
sequenc
avoid
gener
nonspecif
sequenc
enhanc
sensit
detect
cdna
preamplifi
pcr
cycl
min
min
nest
primer
amplifi
realtim
quantit
pcr
siv
dna
gag
cycl
min
use
forward
primer
revers
primer
amplifi
product
detect
hybrid
label
probe
quantit
determin
sampl
show
amplif
replic
deriv
directli
refer
linear
standard
curv
triplic
reaction
dilut
copiesreact
copiesreact
averag
valu
determin
reaction
base
interpol
measur
threshold
cycl
valu
onto
standard
curv
input
templat
copi
number
versu
threshold
cycl
valu
perform
assay
statist
analysi
statist
signific
vivo
neutral
suppress
infect
differ
treatment
group
compar
untreat
group
determin
oneway
analysi
varianc
anova
multiplecomparison
test
unpair
test
graphpad
prism
softwar
use
statist
analysi
differ
consid
statist
signific
p
valu
studi
approv
mous
studi
approv
institut
anim
studi
institut
review
board
albert
einstein
colleg
medicin
complianc
human
anim
experiment
guidelin
us
depart
health
human
servic
adher
nih
guid
care
use
laboratori
anim
macaqu
studi
conduct
biosafeti
level
laboratori
protocol
approv
institut
anim
care
use
committe
institut
laboratori
anim
scienc
chines
academi
medic
scienc
